<DOC>
	<DOC>NCT01799356</DOC>
	<brief_summary>We aimed to compare efficacy and safety of combination therapy with oral ofloxacin, 400 mg twice daily, plus oral metronidazole, 500 mg twice daily, for 14 days, with moxifloxacin monotherapy, 400 mg once daily, for 14 days</brief_summary>
	<brief_title>Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials</brief_title>
	<detailed_description />
	<mesh_term>Pelvic Inflammatory Disease</mesh_term>
	<mesh_term>Pelvic Infection</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Antibiotics, Antitubercular</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>1. Women diagnosed uncomplicated PID 2. Patients age are between 14 with 45 3. Pelvic tenderness and vaginal discharge 1. Urinary Tract Enfections 2. Tuboovarian abscess and complicated PID 3. HÄ±story of antibiotics treatment 4. Other pelvic pain causes 5. Endometriosis 6. Delivery,abortion and surgery within last months</criteria>
	<gender>Female</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Treatment, moksifloksasin</keyword>
</DOC>